Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Lee HJ;Lee HJ; Rao JS; Chang L; Rapoport SI; Kim HW
  • Source:
    Molecular psychiatry [Mol Psychiatry] 2010 Jun; Vol. 15 (6), pp. 602-14. Date of Electronic Publication: 2008 Nov 04.
  • Publication Type:
    Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Specialist Journals Country of Publication: England NLM ID: 9607835 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5578 (Electronic) Linking ISSN: 13594184 NLM ISO Abbreviation: Mol Psychiatry Subsets: MEDLINE
    • Publication Information:
      Publication: 2000- : Houndmills, Basingstoke, UK : Nature Publishing Group Specialist Journals
      Original Publication: Houndmills, Hampshire, UK ; New York, NY : Stockton Press, c1996-
    • Subject Terms:
      Arachidonic Acid/*metabolism ; Bipolar Disorder/*diagnosis ; Bipolar Disorder/*metabolism ; Bupropion/*pharmacology ; Frontal Lobe/*drug effects ; Imipramine/*pharmacology ; Signal Transduction/*drug effects; Animals ; Bupropion/administration & dosage ; Cyclooxygenase 1/biosynthesis ; Cyclooxygenase 2/biosynthesis ; Dinoprostone/biosynthesis ; Drug Administration Schedule ; Frontal Lobe/metabolism ; Humans ; Imipramine/administration & dosage ; Male ; Phospholipases A2, Calcium-Independent/biosynthesis ; Phospholipases A2, Cytosolic/biosynthesis ; Phosphorylation/drug effects ; Rats ; Transcription Factor AP-2/biosynthesis ; Up-Regulation/drug effects
    • Abstract:
      Agents effective against mania in bipolar disorder are reported to decrease turnover of arachidonic acid (AA) in phospholipids and expression of calcium-dependent AA-selective cytosolic phospholipase A(2) (cPLA(2)) in rat brain. In contrast, fluoxetine, an antidepressant that is reported to switch bipolar depressed patients to mania, increases cPLA(2) expression and AA turnover in rat brain. We therefore hypothesized that antidepressants that increase switching to mania generally increase cPLA(2) and AA turnover in brain. To test this hypothesis, adult male CDF-344 rats were administered imipramine and bupropion, with reported high and low switching rates, respectively, at daily doses of 10 and 30 mg kg(-1) i.p., respectively, or i.p. saline (control) for 21 days. Frontal cortex expression of different PLA(2) enzymes and AA turnover rates in brain when the rats were unanesthetized were measured. Compared with chronic saline, chronic imipramine but not bupropion significantly increased cortex cPLA(2) mRNA activity, protein and phosphorylation, expression of the cPLA(2) transcription factor, activator protein-2alpha (AP-2alpha) and AA turnover in phospholipids. Protein levels of secretory phospholipase A(2), calcium-independent phospholipase A(2), cyclooxygenase (COX)-1 and COX-2 were unchanged, and prostaglandin E(2) was unaffected. These results, taken with prior data on chronic fluoxetine in rats, suggest that antidepressants that increase the switching tendency of bipolar depressed patients to mania do so by increasing AA recycling and metabolism in brain. Mania in bipolar disorder thus may involve upregulated brain AA metabolism.
    • References:
      Brain Res. 2007 Feb 23;1134(1):199-205. (PMID: 17204250)
      Psychopharmacology (Berl). 2005 Jun;180(1):12-20. (PMID: 15834538)
      Neurochem Res. 1999 Mar;24(3):399-406. (PMID: 10215514)
      Mol Neurobiol. 2005 Aug;32(1):89-103. (PMID: 16077186)
      Prim Care Companion J Clin Psychiatry. 2005;7(3):106-13. (PMID: 16027765)
      Nat Immunol. 2005 Dec;6(12):1191-7. (PMID: 16369558)
      Biochim Biophys Acta. 1991 Jul 9;1084(2):105-21. (PMID: 1854795)
      Science. 1970 Aug 28;169(3948):883-6. (PMID: 4317401)
      Am J Psychiatry. 2006 Feb;163(2):232-9. (PMID: 16449476)
      Drug Metab Dispos. 1986 Nov-Dec;14(6):692-7. (PMID: 2877828)
      Neurochem Res. 2005 May;30(5):677-83. (PMID: 16176072)
      Biochim Biophys Acta. 1968 Jan 10;152(1):10-9. (PMID: 4296328)
      Brain Res Brain Res Rev. 1992 Sep-Dec;17(3):187-214. (PMID: 1467810)
      Anal Biochem. 1994 Aug 1;220(2):321-3. (PMID: 7978274)
      Neurochem Res. 2008 May;33(5):861-6. (PMID: 18080190)
      J Neurosci Res. 1989 Nov;24(3):413-23. (PMID: 2512392)
      J Neurochem. 2007 Sep;102(6):1918-27. (PMID: 17550430)
      Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
      Neuropsychobiology. 2000;42 Suppl 1:50-1. (PMID: 11093073)
      Arch Gen Psychiatry. 2003 Mar;60(3):261-9. (PMID: 12622659)
      Nature. 2004 Sep 9;431(7005):195-9. (PMID: 15356633)
      Science. 2001 Nov 30;294(5548):1871-5. (PMID: 11729303)
      Neurochem Res. 1997 Jul;22(7):759-65. (PMID: 9232626)
      Am J Clin Nutr. 1994 Aug;60(2):189-94. (PMID: 7913291)
      Biol Psychiatry. 2006 Mar 1;59(5):401-7. (PMID: 16182257)
      J Lipid Res. 2008 Jan;49(1):162-8. (PMID: 17957090)
      J Biol Chem. 2000 Dec 1;275(48):37542-51. (PMID: 10978317)
      Eur Neuropsychopharmacol. 1999 Aug;9 Suppl 4:S109-12. (PMID: 10524836)
      Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):30-41. (PMID: 16091300)
      J Neurochem. 1995 Nov;65(5):2290-8. (PMID: 7595518)
      J Pharmacol Exp Ther. 2002 Sep;302(3):957-62. (PMID: 12183652)
      Biol Psychiatry. 2007 Jan 15;61(2):154-61. (PMID: 16806101)
      J Neurochem. 1990 Jul;55(1):1-15. (PMID: 2113081)
      J Neural Transm (Vienna). 2002 Mar;109(3):433-40. (PMID: 11956963)
      Pol J Pharmacol. 2003 Nov-Dec;55(6):993-9. (PMID: 14730094)
      Neuropsychopharmacology. 2005 Jun;30(6):1064-75. (PMID: 15812572)
      J Clin Psychiatry. 1998 Jul;59(7):374-9. (PMID: 9714266)
      Am J Physiol. 1997 Feb;272(2 Pt 1):C450-6. (PMID: 9124287)
      J Neurochem. 2003 May;85(3):690-6. (PMID: 12694395)
      Cell. 1991 Jun 14;65(6):1043-51. (PMID: 1904318)
      Am J Psychiatry. 1984 Feb;141(2):280-1. (PMID: 6362443)
      Psychopharmacology (Berl). 2005 Nov;183(1):31-40. (PMID: 16220339)
      Am J Psychiatry. 2001 Jun;158(6):906-12. (PMID: 11384898)
      Science. 1987 Sep 4;237(4819):1171-6. (PMID: 2820055)
      Pharmacogenomics J. 2006 Nov-Dec;6(6):413-20. (PMID: 16636684)
      Psychopharmacology (Berl). 2005 Oct;182(1):180-5. (PMID: 15986187)
      Eur Neuropsychopharmacol. 2008 Feb;18(2):128-40. (PMID: 17566715)
      Nature. 1996 Nov 7;384(6604):39-43. (PMID: 8900274)
      Proc Natl Acad Sci U S A. 1990 Mar;87(6):2187-91. (PMID: 2315313)
      Br J Psychiatry. 2006 Aug;189:124-31. (PMID: 16880481)
      Biochem J. 1994 Sep 15;302 ( Pt 3):723-7. (PMID: 7945196)
      Psychopharmacology (Berl). 2005 Jul;180(3):523-9. (PMID: 15719218)
      Mol Psychiatry. 2007 Feb;12(2):151-7. (PMID: 16983392)
      Naunyn Schmiedebergs Arch Pharmacol. 1981 Nov;317(3):209-13. (PMID: 7322212)
      Neurosci Lett. 1996 Dec 20;220(3):171-4. (PMID: 8994220)
      J Neurochem. 1994 Aug;63(2):727-36. (PMID: 8035197)
      Arch Gen Psychiatry. 1973 Mar;28(3):337-41. (PMID: 4569674)
      Neuroreport. 1999 Dec 16;10(18):3887-90. (PMID: 10716228)
      Bipolar Disord. 2003 Dec;5(6):421-33. (PMID: 14636365)
      J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):1S-7S; discussion 7S-9S. (PMID: 8784643)
      Proc Natl Acad Sci U S A. 1990 Oct;87(19):7522-6. (PMID: 1977162)
      Psychopharmacology (Berl). 2007 Jan;190(1):103-15. (PMID: 17093977)
      J Psychopharmacol. 2003 Jun;17(2):149-73; discussion 147. (PMID: 12870562)
      Nature. 1998 Apr 2;392(6675):512-6. (PMID: 9548258)
      Mol Psychiatry. 2002;7(8):845-50. (PMID: 12232777)
      J Lipid Res. 1983 Jan;24(1):83-93. (PMID: 6833884)
      J Biol Chem. 1957 May;226(1):497-509. (PMID: 13428781)
      Biochem Biophys Res Commun. 1994 Nov 30;205(1):6-11. (PMID: 7999086)
      Mol Psychiatry. 2007 Jan;12(1):36-46. (PMID: 16983391)
      J Neural Transm. 1982;54(3-4):219-28. (PMID: 7130974)
      J Biol Chem. 1998 Feb 20;273(8):4449-58. (PMID: 9468497)
      Biochim Biophys Acta. 2006 Sep;1761(9):1050-9. (PMID: 16920015)
      J Neurochem. 2001 May;77(3):796-803. (PMID: 11331408)
      Biol Pharm Bull. 2008 Feb;31(2):246-9. (PMID: 18239281)
      Mol Psychiatry. 2008 Jun;13(6):585-96. (PMID: 18347600)
      Brain Res. 1997 Sep 12;768(1-2):43-8. (PMID: 9369299)
      Arch Gen Psychiatry. 2003 Nov;60(11):1079-88. (PMID: 14609883)
      Methods Enzymol. 1981;72:5-7. (PMID: 7311848)
      Psychopharmacology (Berl). 2006 Jan;184(1):122-9. (PMID: 16344985)
      Biol Psychiatry. 2004 Aug 15;56(4):248-54. (PMID: 15312812)
      Endocrinology. 1997 Jan;138(1):314-21. (PMID: 8977419)
      Lipids. 2003 Apr;38(4):477-84. (PMID: 12848297)
      Arch Gen Psychiatry. 1984 Nov;41(11):1096-104. (PMID: 6437366)
      Bipolar Disord. 2006 Feb;8(1):15-27. (PMID: 16411977)
      Prostaglandins Other Lipid Mediat. 2005 Sep;77(1-4):235-48. (PMID: 16099408)
      Neuropsychopharmacology. 2004 Apr;29(4):649-59. (PMID: 14647482)
      Psychopharmacology (Berl). 2007 Sep;193(4):467-74. (PMID: 17487474)
      Neurochem Res. 2005 May;30(5):597-601. (PMID: 16176062)
    • Grant Information:
      Z01 AG000145-07 United States Intramural NIH HHS
    • Accession Number:
      0 (Transcription Factor AP-2)
      01ZG3TPX31 (Bupropion)
      27YG812J1I (Arachidonic Acid)
      EC 1.14.99.1 (Cyclooxygenase 1)
      EC 1.14.99.1 (Cyclooxygenase 2)
      EC 3.1.1.4 (Phospholipases A2, Calcium-Independent)
      EC 3.1.1.4 (Phospholipases A2, Cytosolic)
      K7Q1JQR04M (Dinoprostone)
      OGG85SX4E4 (Imipramine)
    • Publication Date:
      Date Created: 20081105 Date Completed: 20100907 Latest Revision: 20191003
    • Publication Date:
      20231215
    • Accession Number:
      PMC2874651
    • Accession Number:
      10.1038/mp.2008.117
    • Accession Number:
      18982003